Mutations of ASXL1 and TET2 in aplastic anemia

Haematologica

Volumn 100, Issue 5, 2015, Pages e172-e175

  Huang, Jinbo ^a   Ge, Meili ^a   Lu, Shihong ^a   Shi, Jun ^a   Li, Xingxin ^a   Zhang, Jizhou ^a   Wang, Min ^a   Yu, Wei ^a   Shao, Yingqi ^a   Huang, Zhendong ^a   Zhang, Jing ^a   Nie, Neng ^a   Zheng, Yizhou ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Aplastic anemia; ASXL1; TET2

Indexed keywords

CYCLOSPORIN; THYMOCYTE ANTIBODY; ASXL1 PROTEIN, HUMAN; DNA BINDING PROTEIN; ONCOPROTEIN; REPRESSOR PROTEIN; TET2 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; APLASTIC ANEMIA; BONE MARROW BIOPSY; CHILD; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN TISSUE; IRON DEFICIENCY ANEMIA; LETTER; MAJOR CLINICAL STUDY; MALE; MEGALOBLASTIC ANEMIA; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; PANCYTOPENIA; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; ANEMIA, APLASTIC; BONE MARROW; GENETICS; HETEROZYGOTE; KARYOTYPE; MUTATION; PATHOLOGY;

ANEMIA, APLASTIC; BONE MARROW; DISEASE PROGRESSION; DNA-BINDING PROTEINS; HETEROZYGOTE; HUMANS; KARYOTYPE; MUTATION; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS;

EID: 84929151312     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.120931     Document Type: Letter

References (15)

1. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003; 289(9):1130-1135.
2. Kojima S, Ohara A, Tsuchida M, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood. 2002;100(3):786-790.
3. Li Y, Li X, Ge M, et al. Long-term follow-up of clonal evolutions in 802 aplastic anemia patients: a single-center experience. Ann Hematol. 2011;90(5):529-537.
4. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood. 2002;99(9):3129-3135.
5. Afable MG, Wlodarski M, Makishima H, et al. SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood. 2011; 117(25):6876-6884.
6. Kulasekararaj AG, Jiang J, Smith AE, et al. Somatic mutations identify a sub-group aplastic anemia patients that progress to myelodysplastic syndrome. Blood. 2014;124(17):2698-2704.
7. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF 1. Leukemia. 2010;24(6):1128-1138.
8. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
9. Dicker F, Haferlach C, Sundermann J, et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia, 2010;24(8):1528-1532.
10. Boultwood J, Perry J, Pellagatti A, et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia. 2010;24(5):1062-1065.
11. Fidler C, Watkins F, Bowen DT, Littlewood TJ, Wainscoat JS, Boultwood J. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q). Haematologica. 2004; 89(7):865-866.
12. Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43-70.
13. Young NS, Bacigalupo A, Marsh JC. Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant. 2010;16 (1 Suppl): S119-S125.
14. Wang J, Ai X, Gale RP, et al. TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes. Leuk Res. 2013;37(3):305-311.
15. Olivier Kosmider, Véronique, Gelsi-Boyer, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood. 2009;114(15):3285-3291.